Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Consensus Rating of "Reduce" by Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the nine ratings firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $23.00.

Separately, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday.

Integra LifeSciences Stock Down 3.5 %

Shares of IART stock traded down $0.71 during trading hours on Monday, reaching $19.35. 244,979 shares of the company's stock were exchanged, compared to its average volume of 1,041,467. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -214.75, a P/E/G ratio of 0.73 and a beta of 1.23. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $34.79. The stock's 50 day moving average is $23.50 and its 200-day moving average is $22.25.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the business posted $0.89 earnings per share. Analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently modified their holdings of the company. Quadrant Capital Group LLC grew its holdings in Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the last quarter. Sterling Capital Management LLC increased its position in shares of Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after acquiring an additional 1,931 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares during the period. Covestor Ltd grew its stake in shares of Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $180,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.